New drug combo tested in battle against tough head & neck cancers
Disease control
Terminated
This study tested whether adding an experimental drug called danvatirsen to a standard immunotherapy (pembrolizumab) worked better for people with advanced head and neck cancer that had spread or come back. About 69 participants were randomly assigned to receive either the two-dr…
Phase: PHASE2 • Sponsor: Flamingo Therapeutics NV • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC